Triptorelin Market, by Product Type (Triptorelin pamoate, Triptorelin acetate, and Triptorelin embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer and Central Precocious Puberty), By End User (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) - Global Forecast to 2026

  • Published On : Jul 2018 |
  • Pages : 152 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Triptorelin Market – Global Industry Insights

Gonadotropin-releasing hormone (GnRH) agonists have greater safety and efficacy profile than estrogens and anti-androgens among various therapies of achieving medical castration. Furthermore, slow-release formulations of GnRH agonists offer patients flexibility, improves quality of life, and eventually reduce cost.

Most of the times, prostate cancer progresses with increasing testosterone hormone. Moreover, the production of testosterone can be stopped by surgically removing the testicles or thorough medication therapy. Triptorelin is GnRH agonists which is designed to stop the tentacles from making testosterone. This eventually reduces testosterone levels and minimizes progression of prostate cancer.

Triptorelin is a decapeptide analogue of Luteinising Hormone-Releasing Hormone (LHRH, also called gonadotropin-releasing hormone [GnRH]). Triptorelin is extensively used in palliative treatment of hormone dependent advanced prostate cancer.

Moreover, according to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin were extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

Furthermore, triptorelin is indicated for the treatment of pediatric patients two years of age and older with Central Precocious Puberty (CPP). In July 2017, U.S. Food and Drug Administration (FDA), approved Arbor Pharmaceuticals’: Triptodur, in pediatric patients with central precocious puberty. The approval follows a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty), which examines prepubertal luteinizing hormone levels using triporelin therapy. Study demonstrated a return to pre-pubertal luteinizing hormone (LH) levels in 93% of enrolled patients, with pre-pubertal luteinizing hormone (LH) suppression maintained at 12 months by 98% of patients.

The global triptorelin market size was valued at US$ 426.4 Mn in 2017, and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).

Global Triptorelin Market Share, By Product Type: 2018 & 2026

Source: Coherent Market Insights Analysis (2018)

Extended Application of Triptorelin in Various Treatment Modalities is expected to Drive Market Growth during the Forecast Period

The GnRH agonist, triptorelin is a first-line hormonal therapy, which offers efficacy and safety in clinical trials of patients with non-metastatic or metastatic prostate cancer. Furthermore, triptorelin has been increasingly studied for varied treatment options, present in clinical development phases. For instance, GnRH analogue, triptorelin is being studied to analyze their efficacy and safety for HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients. According to ClinicalTrials.gov, in May 2018, this study was conducted by Immune System Regulation AB, and currently in phase II clinical stage.

Triptorelin is further being studied to analyze effects of adjuvant hormonal therapy treatments of Tamoxifen, Letrozole and Letrozole + Zoledronate on bone loss in breast cancer patients. According to ClinicalTrials.gov, in July 2017, this study was sponsored by National Cancer Institute (NCI), Naples; and currently present in phase III clinical stage. Moreover, triptorelin market shows lucrative revenue growth in the near future, with the successful completion of this study and potential launch of new products during the forecast period.

Moreover, higher efficacy and effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is expected to drive the triptorelin market growth. For instance, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

Furthermore, increasing research and development activities focused on application of androgen deprivation therapy with triptorelin to lower progression of salivary gland cancer expressing androgen receptors. For instance, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for treatment of salivary gland cancer. Under the collaboration, Debiopharm International SA will supply triptorelin pamoate 3.75 mg 1-month formulation to patients suffering from salivary gland cancer participating in a clinical study sponsored by EORTC. During the clinical study, researchers will evaluate the efficacy and safety of androgen chemotherapy versusandrogen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.

Global Triptorelin Market Share, By Application: 2018 & 2026

Source: Coherent Market Insights Analysis (2018)

Increasing Prevalence of Prostate Cancer among Global Population is expected to Aid in Market Growth

Incensing prevalence of prostate cancer worldwide and wide applications of triptorelin in prostate cancer treatment to limit the cancer progression by reducing the testosterone synthesized by body is expected to drive growth of triptorelin market during the forecast period.

For instance, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, around 68% of prostate cancer cases were registered in the developed economies. Highest incidence of prostate cancer was reported in Oceania and North America, while lowest incidence was reported in Asia and Africa.

Moreover, according to the Cancer Research U.K., in 2015, around 47,151 new cases of prostate cancer were registered in the U.K. Furthermore, prostate cancer accounted for 13% of the total cancer cases in the U.K., in 2015. Prostate cancer is the second-most common cause of cancer deaths among males in the U.K. in 2014, accounting for 13% of all cancer deaths among males. In addition, according to the same source, in 2014, around 11,287 prostate cancer deaths were recorded among males in the U.K. The crude mortality rate shows that there were 36 prostate cancer deaths for every 100,000 males in the country.

Key players operating in triptorelin market include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.

Triptorelin is a peptide formulation for injection that was developed mainly for the treatment of advanced metastatic prostate cancer. Furthermore, other indications developed subsequently include the treatment of uterine fibroids (a benign tumor of muscle tissues in the uterus), endometriosis (proliferation of endometrial tissue, the mucous membrane that lines the uterine wall outside the reproductive tract) prior to surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility (in vitro fertilization). Other modalities of triptorelin such as triptorelin acetate, triptorelin pamoate and triptorelin embonate are also used for prostate cancer treatment.

Market Dynamics

Triptorelin market is expected to witness lucrative growth opportunities during forecast period, owing to increasing incidence of prostate cancer and salivary gland cancer and increasing prevalence of central precocious puberty among the young patients below age eight and nine years, worldwide. For instance, according to National Organization for Rare Disorders (NORD), 2016 data findings, Central Precocious Puberty (CPP), accounted for 1 to 5 in 10,000 children with a female to male ratio of about 20:1, in U.S.

In March 2017, Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies approved a new indication of Decapeptyl (triptorelin). According to these new indication, Decapeptyl (triptorelin) will be used as adjuvant treatment in combination with tamoxifen or aromatase inhibitor for endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy. This would enhance the revenue for growth for triptorelin market, during forecast period.

Furthermore, higher efficacy and tolerability of triptorelin in suppression of gonadotropin secretion in prostate cancer and precocious puberty is increasing adoption of triptorelin in the market.

Key features of the study:

  • This report provides in-depth analysis of triptorelin market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global triptorelin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include Ipsen, Bachem, Ferring Pharmaceuticals Pvt Ltd., Chengdu Tiantaishan pharmaceutical Co., Ltd., Tecnofarma, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), Debiopharm Group, and Arbor Pharmaceuticals, LLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global triptorelin market report caters to various stakeholders in this industry including investors, suppliers, triptorelin based product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the triptorelin market.

Detailed Segmentation:

  • Global Triptorelin Market, By Drug Type:
    • Triptorelin Pamoate
    • Triptorelin Acetate
    • Triptorelin Embonate
  • Global Triptorelin Market, By Application:
    • Prostate Cancer
    • Radical Prostatectomy 
    • Endometriosis
    • Salivary Gland Cancer
    • Central Precocious Puberty
  • Global Triptorelin Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Triptorelin Market, By Geography:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Drug Type:
        • Decapeptyl SR
        • Trelstar
        • Decapeptyl SR
        • Gonapeptyl depot
        • Salvacyl
        • Triptorelin pamoate
        • Triptorelin acetate
        • Triptorelin embonate
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Europe
      • By Country:
        • Germany
        • France
        • Italy
        • UK
        • Spain
        • Russia
        • Rest of Europe
      • By Drug Type:
        • Triptorelin pamoate
          • Decapeptyl SR
          • Trelstar
        • Triptorelin acetate
          • Decapeptyl SR
          • Gonapeptyl depot
        • Triptorelin embonate
          • Salvacyl
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Asia Pacific
      • By Country: 
        • China
        • India
        • Japan
        • South Korea
        • Australia
        • Rest of Asia Pacific
      • By Drug Type:
        • Triptorelin pamoate
          • Decapeptyl SR
          • Trelstar
        • Triptorelin acetate
          • Decapeptyl SR
          • Gonapeptyl depot
        • Triptorelin embonate
          • Salvacyl
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Middle East
      • By Country: 
        • GCC
        • Israel
        • Rest of Middle East
      • By Drug Type:
        • Triptorelin pamoate
          • Decapeptyl SR
          • Trelstar
        • Triptorelin acetate
          • Decapeptyl SR
          • Gonapeptyl depot
        • Triptorelin embonate
          • Salvacyl
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Latin America
      • By Country: 
        • Brazil
        • Argentina
        • Mexico
        • Rest of Latin America
        •  
      • By Drug Type:
        • Triptorelin pamoate
          • Decapeptyl SR
          • Trelstar
        • Triptorelin acetate
          • Decapeptyl SR
          • Gonapeptyl depot
        • Triptorelin embonate
          • Salvacyl
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
    • Africa
      • By Country: 
        • South Africa
        • Central Africa
        • North Africa
      • By Drug Type:
        • Triptorelin pamoate
          • Decapeptyl SR
          • Trelstar
        • Triptorelin acetate
          • Decapeptyl SR
          • Gonapeptyl depot
        • Triptorelin embonate
          • Salvacyl
      • By Application
        • Prostate Cancer
        • Radical Prostatectomy
        • Endometriosis
        • Salivary Gland Cancer
        • Central Precocious Puberty
      • By Distribution Channel:
        • Hospital Pharmacy
        • Retail Pharmacy
        • Online Pharmacy
  • Company Profiles
    • Ipsen *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Developments
      • Strategies
    • Bachem
    • Ferring Pharmaceuticals Pvt Ltd.
    • Chengdu Tiantaishan pharmaceutical Co., Ltd.
    • Tecnofarma
    • Reddy’s Laboratories Ltd.
    • Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
    • Debiopharm Group
    • Arbor Pharmaceuticals, LLC

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Type
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Market Trends
    • Epidemiology
    • New Product Approvals/Launch
    • Mergers/ Acquisition
    • Strategic Collaborations
    • PEST Analysis
  4. Global Triptorelin Market, By Drug Type, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Triptorelin pamoate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Triptorelin acetate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Triptorelin embonate
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Triptorelin Market, By Application, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Prostate Cancer
      • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
    • Radical Prostatectomy 
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Endometriosis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Salivary Gland Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Central Precocious Puberty
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Triptorelin Market, By Distribution Channel, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 - 2026
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Triptorelin Market, By Regions, 2016 - 2026 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017 - 2026
    • North America
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Drug Type, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Application, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 - 2026 (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Ipsen
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      •  Bachem 
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Ferring Pharmaceuticals Pvt Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Chengdu Tiantaishan pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Tecnofarma
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Dr. Reddy’s Laboratories Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.)
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Debiopharm Group
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Arbor Pharmaceuticals, LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Analyst Views
    • Research Methodology
    • About Us and Sales Contact

*Browse 26 market data tables and 21 figures on "Triptorelin Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.